20/20 BioLabs Reports Q1 2026 Financial Results
Health
Earnings
IPO:
Feb 19, 2026
Industry:
TESTING LABORATORIES
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
20/20 BioLabs Reports Q1 2026 Financial Results and Strategic Progress
Gaithersburg, MD - 20/20 BioLabs, Inc. (Nasdaq: AIDX), a developer of AI-powered blood tests for cancer and chronic disease detection, announced its financial and operational results for the first quarter ending March 31, 2026.
Financial Highlights
... Read on — Members only
About 20/20 Biolabs, Inc.
We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases.
Health
Daily overview of upcoming SPAC and IPO events – from initial announcement to definitive agreement and public listing.
Discover last week’s SPAC and IPO highlights, key trends, and market updates. Stay informed with SpacStar.